

## Present and future collaborative drug discovery informatics innovations

Barry A Bunin

Collaborative Drug Discovery, Inc., USA



### Abstract

Collaborative Drug Discovery (CDD) provides a whole solution for today's biological and chemical data needs, differentiated by ease-of-use and superior collaborative capabilities. CDD Vault® software includes Activity & Registration, Visualization, Inventory, and ELN capabilities. Researchers can archive, mine, and securely collaborate within CDD Vault. Collaborative hypothesis generation and evaluation allow multiple perspectives for multi-parameter optimization.

CDD's Research Informatics Group invents bleeding edge technologies. For example, the recently developed BioHarmony data store provides real-time semantic drug reports online at [www.biometadata.com](http://www.biometadata.com). In addition, BioHarmony Annotator allows more sophisticated assay registration and management.

Case studies will be shared from industry (Jubilant Biosys), government (NIH Neuroscience Blueprint), non-profit (Gates Foundation), and numerous leading academic collaborations.

### Biography

Barry A Bunin, PhD is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen \$50 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly and Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen's \$10.4 Billion acquisition of Onyx Pharmaceuticals

5<sup>th</sup> World Conference on Pharmaceutical Research and Drug Management | July 15<sup>th</sup>, 2021

**Citation:** Barry A. Bunin, Present and future collaborative drug discovery informatics innovations, Drug Discovery 2021, 5<sup>th</sup> World Conference on Pharmaceutical Research and Drug Management | July 15<sup>th</sup>, 2021, 10